Stephens Has Lowered Expectations for OptimizeRx (NASDAQ:OPRX) Stock Price

OptimizeRx (NASDAQ:OPRX) had its price target lowered by investment analysts at Stephens from $17.00 to $10.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Stephens’ price objective points to a potential upside of 48.37% from the stock’s previous close.

Several other research analysts have also weighed in on the stock. Citizens Jmp upped their price objective on shares of OptimizeRx from $23.00 to $24.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. Wall Street Zen raised shares of OptimizeRx from a “buy” rating to a “strong-buy” rating in a research note on Sunday, December 14th. Stifel Nicolaus lowered their price target on shares of OptimizeRx from $21.00 to $17.00 and set a “buy” rating on the stock in a report on Friday. Zacks Research lowered OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Monday, December 15th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of OptimizeRx in a research report on Monday, December 22nd. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, OptimizeRx presently has a consensus rating of “Moderate Buy” and an average price target of $17.57.

OptimizeRx Stock Down 10.5%

Shares of OptimizeRx stock opened at $6.74 on Friday. OptimizeRx has a 1 year low of $3.99 and a 1 year high of $22.25. The company has a market cap of $125.63 million, a P/E ratio of 25.92 and a beta of 1.20. The company has a current ratio of 3.05, a quick ratio of 3.05 and a debt-to-equity ratio of 0.20. The stock has a 50-day moving average price of $10.52 and a 200 day moving average price of $14.72.

OptimizeRx (NASDAQ:OPRX) last released its earnings results on Saturday, January 31st. The company reported $0.51 earnings per share for the quarter. OptimizeRx had a return on equity of 10.81% and a net margin of 4.69%. As a group, analysts expect that OptimizeRx will post -0.33 EPS for the current fiscal year.

OptimizeRx announced that its board has initiated a share buyback plan on Thursday, March 5th that allows the company to repurchase $10.00 million in shares. This repurchase authorization allows the company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of OptimizeRx by 15.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,059,109 shares of the company’s stock valued at $21,712,000 after purchasing an additional 138,224 shares during the last quarter. Royce & Associates LP raised its holdings in OptimizeRx by 0.7% during the fourth quarter. Royce & Associates LP now owns 682,030 shares of the company’s stock valued at $8,362,000 after buying an additional 4,700 shares in the last quarter. Kennedy Capital Management LLC raised its holdings in OptimizeRx by 42.8% during the third quarter. Kennedy Capital Management LLC now owns 674,918 shares of the company’s stock valued at $13,836,000 after buying an additional 202,446 shares in the last quarter. Rice Hall James & Associates LLC lifted its position in shares of OptimizeRx by 8.2% in the fourth quarter. Rice Hall James & Associates LLC now owns 590,674 shares of the company’s stock worth $7,242,000 after buying an additional 44,858 shares during the last quarter. Finally, Parkman Healthcare Partners LLC boosted its stake in shares of OptimizeRx by 0.4% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 509,611 shares of the company’s stock worth $10,447,000 after acquiring an additional 2,188 shares in the last quarter. Institutional investors own 76.47% of the company’s stock.

OptimizeRx News Roundup

Here are the key news stories impacting OptimizeRx this week:

• Positive Sentiment: Q4 earnings and revenue beat expectations — OPRX reported stronger-than-expected results (EPS and revenue topped consensus), supporting the company’s underlying growth narrative. Q4 Results
• Positive Sentiment: Board authorized a $10.0M share repurchase program (up to ~6.8% of shares), a shareholder-friendly move that typically supports share price over time by reducing float. Buyback Announcement
• Neutral Sentiment: Roth MKM lowered its price target from $32 to $18 but kept a “buy” rating — still a materially higher target than current levels, creating mixed signals (cut in optimism but continued buy conviction). Roth MKM PT Change
• Neutral Sentiment: Multiple brief trading halts for OPRX were reported today due to LULD pauses — technical market safeguards that can amplify volatility but do not convey fundamental news.
• Negative Sentiment: FY2026 revenue guidance came in at $109M–$114M versus consensus near $122M — a notable shortfall that likely drove investor disappointment and downward pressure on the stock. Guidance Story
• Negative Sentiment: B. Riley reaffirmed its buy rating but cut its price target from $28 to $11 — another analyst reduction that removes prior upside and likely contributed to selling pressure. B. Riley PT Cut
• Negative Sentiment: Stephens trimmed its target to $10 and set an “equal weight” rating, signaling a more cautious view and reducing analyst-driven upside expectations. Stephens PT Change

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.